It was a pleasure to speak with Dr David Hunter (Harvard Medical School, Boston, MA, USA) about the Luminopia One Amblyopia Vision Improvement Study, which were presented at AAPOS 2021.<\/p>\n
Questions<\/strong><\/p>\n
Speaker Disclosure:<\/strong> David Hunter discloses the following: Advisor and equity holder, Luminopia, Inc. Board member and equity holder, Rebion Inc.<\/p>\n
Support:<\/strong> Interview and filming supported by Touch Medical Media Ltd.<\/p>\n
Filmed in coverage of AAPOS 2021.<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"
It was a pleasure to speak with Dr David Hunter (Harvard Medical School, Boston, MA, USA) about the Luminopia One Amblyopia Vision Improvement Study, which were presented at AAPOS 2021. Questions What are the aims and design of the Luminopia One Amblyopia Vision Improvement Study? What are the primary and secondary outcome measures of the […]<\/p>\n","protected":false},"featured_media":22601,"template":"","class_list":["post-22603","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-paediatric-ophthalmology","video_categories-aapos-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchophthalmology.com\/wp-json\/wp\/v2\/media_gallery\/22603"}],"collection":[{"href":"https:\/\/touchophthalmology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchophthalmology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":2,"href":"https:\/\/touchophthalmology.com\/wp-json\/wp\/v2\/media_gallery\/22603\/revisions"}],"predecessor-version":[{"id":22611,"href":"https:\/\/touchophthalmology.com\/wp-json\/wp\/v2\/media_gallery\/22603\/revisions\/22611"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchophthalmology.com\/wp-json\/wp\/v2\/media\/22601"}],"wp:attachment":[{"href":"https:\/\/touchophthalmology.com\/wp-json\/wp\/v2\/media?parent=22603"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}